Caris Life Sciences (CAI) EPS (Basic) (2024 - 2026)

Caris Life Sciences' EPS (Basic) history runs 3 years deep, the most recent figure standing at -$0.0 for Q1 2026.

• In Q1 2026, EPS (Basic) rose 99.95% year-over-year to -$0.0; the TTM figure through Mar 2026 stood at -$1.46 (up 86.03% YoY), while the FY2025 annual figure was -$3.22, up 69.81% from the prior year.
• EPS (Basic) for Q1 2026 stood at -$0.0, down from $0.49 in the prior quarter.
• The five-year high for EPS (Basic) was $0.49 in Q4 2025, with the low at -$7.97 in Q2 2025.
• The 3-year median for EPS (Basic) is -$2.14 (2024), against an average of -$2.23.
• Peak annual rise in EPS (Basic) reached 128.09% in 2025, while the deepest fall reached 213.88% in 2025.
• Caris Life Sciences' EPS (Basic) stood at -$1.75 in 2024, then soared by 128.09% to $0.49 in 2025, then sank by 100.37% to -$0.0 in 2026.
• Business Quant data shows CAI's EPS (Basic) at -$0.0 in Q1 2026, $0.49 in Q4 2025, and $0.09 in Q3 2025.